Jerneja Tomsic
Overview
Explore the profile of Jerneja Tomsic including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
823
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jones V, Yin H, Yuan Y, Wang Y, Li S, Aljaber D, et al.
Sci Rep
. 2025 Feb;
15(1):7220.
PMID: 40021703
Despite endocrine therapy (ET), approximately 20-40% of Stage I-III estrogen receptor-positive breast cancer (ER + BC) patients experience recurrence. Recurrence while on ET is indicative of ET resistance. This study...
2.
Mukund K, Veraksa D, Frankhouser D, Yang L, Tomsic J, Pillai R, et al.
bioRxiv
. 2025 Feb;
PMID: 39990419
Background-: Triple-negative breast cancer is a prevalent breast cancer subtype with the lowest 5-year survival. Several factors contribute to its treatment response, but the inherent molecular and cellular tumor heterogeneity...
3.
Vidal C, Alva-Ornelas J, Chen N, Senapati P, Tomsic J, Robles V, et al.
Cancers (Basel)
. 2024 Aug;
16(15).
PMID: 39123463
Background: Epigenetic changes link medical, social, and environmental factors with cardiovascular and kidney disease and, more recently, with cancer. The mechanistic link between metabolic health and epigenetic changes is only...
4.
Mukund K, Alva-Ornelas J, Maddox A, Murali D, Veraksa D, Saftics A, et al.
Cancers (Basel)
. 2024 Feb;
16(3).
PMID: 38339304
Trastuzumab therapy in HER2+ breast cancer patients has mixed success owing to acquired resistance to therapy. A detailed understanding of downstream molecular cascades resulting from trastuzumab resistance is yet to...
5.
Tomsic J, Caserta E, Pon C, Gualerzi C
Int J Mol Sci
. 2021 Dec;
22(24).
PMID: 34948034
Substitution of the conserved Histidine 448 present in one of the three consensus elements characterizing the guanosine nucleotide binding domain (IF2 G2) of translation initiation factor IF2 resulted in impaired...
6.
Frankhauser D, Jovanovic-Talisman T, Lai L, Yee L, Wang L, Mahabal A, et al.
WIREs Mech Dis
. 2020 Oct;
13(2):e1506.
PMID: 33001587
Over 90% of breast cancer is cured; yet there remain highly aggressive breast cancers that develop rapidly and are extremely difficult to treat, much less prevent. Breast cancers that rapidly...
7.
Tomsic J, Smorlesi A, Caserta E, Giuliodori A, Pon C, Gualerzi C
Int J Mol Sci
. 2020 Jan;
21(3).
PMID: 31979156
The conserved Histidine 301 in switch II of IF2 G2 domain was substituted with Ser, Gln, Arg, Leu and Tyr to generate mutants displaying different phenotypes. Overexpression of IF2H301S, IF2H301L...
8.
Natarajan R, Aljaber D, Au D, Thai C, Sanchez A, Nunez A, et al.
Int J Environ Res Public Health
. 2020 Jan;
17(2).
PMID: 31941024
During puberty, a woman's breasts are vulnerable to environmental damage ("window of vulnerability"). Early exposure to environmental carcinogens, endocrine disruptors, and unhealthy foods (refined sugar, processed fats, food additives) are...
9.
Genutis L, Tomsic J, Bundschuh R, Brock P, Williams M, Roychowdhury S, et al.
Thyroid
. 2019 Feb;
29(4):523-529.
PMID: 30747051
Background: Inactivation of DNA mismatch repair (MMR) and the resulting microsatellite instability (MSI) are frequently observed in endometrial, stomach, and colorectal cancers, as well as more rarely in other solid...
10.
Tomsic J, Fultz R, Liyanarachchi S, Genutis L, Wang Y, Li W, et al.
Oncotarget
. 2016 Dec;
8(4):6475-6482.
PMID: 28031538
Papillary Thyroid Carcinoma (PTC) displays one of the highest familiality scores of all cancers as measured by case-control studies, yet only a handful of genes have been implicated until now....